Lenalidomide, a derivative of thalidomide, has emerged as a cornerstone in the treatment of hematologic malignancies. As an immunomodulatory drug (IMiD), it exhibits potent anti-cancer, anti-inflammatory, and anti-angiogenic properties. Its efficacy has been well-documented in multiple myeloma (MM), myelodysplastic syndromes (MDS), and certain types of lymphoma. With continuous advancements in...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)